Review decision – October 2019
Decision to move the existing TA423 guidance to the static list
We would like to update you on the decision made regarding the review of the existing guidance on TA423; Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens.
TA423 includes an optimised recommendation for eribulin as a treatment option for people with locally advanced or metastatic breast cancer only if disease has progressed after at least 2 chemotherapy regimens (that is, as a third-line treatment option). The full marketing authorisation for eribulin also allows it to be used after at least 1 chemotherapy regimen (that is, as a second-line treatment option). This is covered in TA515 which does not recommend eribulin for people who have had only 1 chemotherapy regimen. Therefore, the focus of this review proposal is eribulin as a third-line treatment option.
In TA423 the main areas of uncertainty were around utility values after disease progression, the methods used to calculate dose and the costs of the comparator and subsequent treatment.
No relevant new evidence has been identified from the literature searches and no new NICE guidance has been published specifically for third-line treatment of advanced or metastatic breast cancer. Overall, no new evidence has been identified that is likely to change the existing recommendations in TA423.
NICE has decided to proceed with this proposal without consultation.
Consequently, TA423 will move to the ‘static list’ of technology appraisals. Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.
This page was last updated: